Regeneron registers trial of ALN-CIDEB in Metabolic Dysfunction-Associated Steatotic Liver Disease
This study was first posted on ClinicalTrials.gov on October 2, 2026. The trial plans to enroll 1500 participants and plans to start on November 6, 2026, with primary completion on March 3, 2029.
Primary source
ClinicalTrials.gov registry record, October 2, 2026
Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD)
Read the source: Trial to Evaluate ALN-CIDEB in Adults With Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) clinicaltrials.gov
Machine-summarized from the source above; not independently reported. How we use automation